Degradation of molecules in thawed biological samples is one of the biggest challenges for all bioanalytical laboratories. During the January SLAS conference in San Diego, CA, CryoXtract was nominated for an innovation award based on a study of the use of frozen aliquotting for the bioanalysis of labile compounds (found here). During a podium presentation, authors Glenn Smith and Joe Fraone outlined the results of the collaborative study with GlaxoSmithKline.
As outlined in the presentation, frozen aliquotting can improve the reliability of bioanalytical data by eliminating freeze/thaw induced degradation of labile drug molecules. Key benefits include the generation of higher quality pre-clinical pharmacokinetic (PK) data, more accurate dose selection for toxicity studies, improved reproducibility of incurred sample reanalysis (ISR) results, and the identification and validation of previously elusive biomarkers.